A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

被引：0
|
作者：
Mulligan, Stephen P. [1 ,2 ,3 ]
Gill, Devinder [4 ]
Turner, Paul [5 ]
Renwick, William E. P. [6 ]
Latimer, Maya [7 ]
Mackinlay, Naomi [1 ]
Berkahn, Leanne [8 ]
Simpson, David [9 ]
Campbell, Philip [10 ]
Forsyth, Cecily J. [11 ]
Cull, Gavin [12 ]
Harrup, Rosemary [13 ]
Sulda, Melanie [14 ]
Best, Giles [15 ]
Bressel, Mathias [16 ]
Di Iulio, Juliana [16 ]
Kuss, Bryone J. [14 ,17 ]
机构：
[1] Royal N Shore Hosp, Sydney, NSW, Australia
[2] CLL Australian Res Consortium CLLARC, Sydney, NSW, Australia
[3] Australasian Leukaemia & Lymphoma Grp ALLG, Melbourne, Australia
[4] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[5] Austin Hosp, Melbourne, Vic 3084, Australia
[6] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[7] Canberra Hosp, Canberra, ACT, Australia
[8] Auckland Hosp, Auckland, New Zealand
[9] North Shore Hosp, Auckland, New Zealand
[10] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia
[11] Gosford Hosp, Gosford, Australia
[12] Sir Charles Gairdner Hosp, Perth, WA, Australia
[13] Royal Hobart Hosp, Hobart, Tas, Australia
[14] Flinders Med Ctr, Adelaide, SA, Australia
[15] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia
[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Flinders Univ S Australia, Adelaide, SA 5001, Australia
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 42 条
  • [21] RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY
    Hillmen, P.
    Gribben, J. G.
    Follows, G. A.
    Milligan, D.
    Sayala, H. A.
    Moreton, P.
    Oscier, D. G.
    Dearden, C. E.
    Kennedy, D. B.
    Pettitt, A. R.
    Nathwani, A.
    Cohen, D.
    Rawstron, A.
    Pocock, C. F.
    ANNALS OF ONCOLOGY, 2011, 22 : 123 - 123
  • [22] Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome
    Laurenti, Luca
    De Padua, Laura
    Tarnani, Michela
    Piccirillo, Nicola
    Falcucci, Paolo
    D'Arena, Giovanni
    Innocenti, Idanna
    Marietti, Sara
    Efremov, Dimitar G.
    Chiusolo, Patrizia
    Zini, Gina
    Sora, Federica
    Sica, Simona
    Leone, Giuseppe
    ANNALS OF HEMATOLOGY, 2011, 90 (01) : 59 - 65
  • [23] Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome
    Luca Laurenti
    Laura De Padua
    Michela Tarnani
    Nicola Piccirillo
    Paolo Falcucci
    Giovanni D’Arena
    Idanna Innocenti
    Sara Marietti
    Dimitar G. Efremov
    Patrizia Chiusolo
    Gina Zini
    Federica Sora’
    Simona Sica
    Giuseppe Leone
    Annals of Hematology, 2011, 90 : 59 - 65
  • [24] Germline IgVH, del(17p13.1) and del(11q22.3) predict duration of response in patients affected by chronic lymphocytic leukaemia treated with oral fludarabine and cyclophosphamide as first-line therapy
    Laurenti, Luca
    Efremov, Dimitar
    Tarnani, Michela
    de Padua, Laura
    Piccirillo, Nicola
    Chiusolo, Patrizia
    Sora, Federica
    Sica, Simona
    Zini, Gina
    Garzia, Mariagrazia
    Leone, Giuseppe
    BLOOD, 2007, 110 (11) : 253B - 253B
  • [25] Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM
    Delmer, Alain
    Tournilhac, Olivier
    Lepretre, Stephane
    Cazin, Bruno
    Feugier, Pierre
    Dreyfus, Brigitte
    Mahe, Beatrice
    Leporrier, Michel
    Michallet, Anne-Sophie
    Jaccard, Arnaud
    Divine, Marine
    Levy, Vincent
    Cymbalista, Florence
    Letestu, Remi
    BLOOD, 2011, 118 (21) : 1667 - 1667
  • [26] Combined therapy of rituximab, fludarabine and cyclophosphamide (R-FC) as a first-line treatment is safe and efficacious for younger patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Ranze, OP
    Arland, M
    Hoffkes, HG
    BLOOD, 2003, 102 (11) : 355B - 356B
  • [27] Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
    Greil, Richard
    Obrtlikova, Petra
    Smolej, Lukas
    Kozak, Tomas
    Steurer, Michael
    Andel, Johannes
    Burgstaller, Sonja
    Mikuskova, Eva
    Gercheva, Liana
    Nosslinger, Thomas
    Papajik, Tomas
    Ladicka, Miriam
    Girschikofsky, Michael
    Hrubisko, Mikulas
    Jager, Ulrich
    Fridrik, Michael
    Pecherstorfer, Martin
    Kralikova, Eva
    Burcoveanu, Cristina
    Spasov, Emil
    Petzer, Andreas
    Mihaylov, Georgi
    Raynov, Julian
    Oexle, Horst
    Zabernigg, August
    Flochova, Emilia
    Palasthy, Stanislav
    Stehlikova, Olga
    Doubek, Michael
    Altenhofer, Petra
    Pleyer, Lisa
    Melchardt, Thomas
    Klingler, Anton
    Mayer, Jiri
    Egle, Alexander
    LANCET HAEMATOLOGY, 2016, 3 (07): : E317 - E329
  • [28] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [29] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara F.
    Bahlo, Jasmin
    Maurer, Christian
    Lange, Elisabeth
    Koppler, Hubert
    Kiehl, Michael G.
    Sokler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Kochling, Georg
    Ploger, Christoph
    Gregor, Michael
    Plesner, Torben
    Herling, Marco
    Fischer, Kirsten
    Dohner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [30] Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2nd line therapy of B-chronic lymphocytic leukaemia (B-CLL):: The FLUSALEM study.
    Egle, Alexander
    Tinhofer, Inge
    Russ, G.
    Rass, C.
    Greil, Richard
    BLOOD, 2006, 108 (11) : 336B - 336B
12345